SEARCH

SEARCH BY CITATION

References

  • Aarnoutse R (2011) Pharmacogenetics of Antituberculosis drugs. In: Antituberculosis Chemotherapy Prog Respir Res. 1st edn. (eds P Donald & P Helden) Karger, Basel, pp. 176190.
  • Chaulet P (1992) The supply of antituberculosis drugs and national drugs policies. Tubercle and Lung Disease73, 295304.
  • Chideya S, Winston CA, Peloquin CA et al. (2009) Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clinical Infectious Diseases48, 16851694.
  • De Onis M, Onyango AW, Borghi E, Siyam A, Nishida C & Siekmann J (2007) Development of a WHO growth reference for school-aged children and adolescents. Bulletin of the World Health Organization85, 660667.
  • Donald PR (2011) Antituberculosis drug-induced hepatotoxicity in children. Pediatric Reports3, e16.
  • Graham SM, Bell DJ, Nyirongo S, Hartkoorn R, Ward SA & Molyneux EM (2006) Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy50, 407413.
  • Gumbo T, Louie A, Liu W et al. (2007) Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrobial Agents and Chemotherapy51, 23292336.
  • Gupta P, Roy V, Sethi GR & Mishra TK (2007) Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses. British Journal of Clinicial Pharmacology65, 423427.
  • Hall RG, Leff RD & Gumbo T (2009) Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy29, 14681481.
  • Holdiness MR (1984) Clinical pharmacokinetics of the antituberculosis drugs. Clinical Pharmacokinetics9, 511544.
  • Lin MY, Lin SJ, Chan LC & Lu YC (2010) Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease14, 806818.
  • Martínez H, Rodriguez-Larralde A, Izaguirre MH & De Guerra DC (2007) Admixture estimates for Caracas, Venezuela, based on autosomal, Y-chromosome and mtDNA markers. Human Biology79, 201213.
  • McIlleron H, Willemse M, Werely CJ, Hussey GD et al. (2009) Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. Clinical Infectious Diseases48, 15471553.
  • Miscoria G, Leneveu A, Walle C & Roux A (1988) Application d’une méthode de dosage de l’Isoniazide et de l’Acétylisoniazide par chromatographie liquide haute performance à la détermination du phénotype d’acétylation. Annales de Biologie Clinique (Paris)46, 734740.
  • Pan American Health Organization PAHO (2006) Plan regional de Tuberculosis 2006–2015. http://www.paho.org/spanish/ad/dpc/cd/tb-reg-plan-2006-15.pdf
  • Pariente-Khayat A, Rey E, Gendrel D et al. (1997) Isoniazid acetylation metabolic ratio during maturation in children. Clinical Pharmacololgy & Therapeutics62, 377383.
  • Parkin DP, Vandenplas S, Botha FJ et al. (1997) Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. American Journal of Respiratory and Critical Care Medicine155, 17171722.
  • Peloquin CA (1991) Antituberculosis drugs: pharmacokinetics. In: Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. 1st edn. (ed. L Heifets) CRC Press, Boca Raton Florida, pp. 5988.
  • Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs62, 21692183.
  • Peloquin CA (2011) Pharmacokinetics of anti-tuberculosis agents: current issues. Lecture at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, September 17–20.
  • Ramachandran G, Hemanth Kumar AK & Sekar L et al. (2010) Influence of age and nutritional status on the pharmacokinetics of anti-tuberculosis drugs in children with tuberculosis. In: Abstract Book 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs. http://www.virology-education.com
  • Ruslami R, Nijland HM, Alisjahbana B, Parwati I, Van Crevel R & Aarnoutse RE (2007) Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrobial Agents and Chemotherapy51, 25462551.
  • Schaaf HS, Parkin DP, Seifart HI et al. (2005) Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Archives of Disease in Childhood90, 614618.
  • Schaaf HS, Willemse M, Cilliers K et al. (2009) Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. BMC Medicine7, 19.
  • Thee S, Detjen A, Wahn U & Magdorf K (2008) Pyrazinamide serum levels in childhood tuberculosis. International Journal of Tuberculosis and Lung Disease12, 10991101.
  • Thee S, Detjen A, Wahn U & Magdorf K (2009) Rifampicin serum levels in childhood tuberculosis. International Journal of Tuberculosis and Lung Disease13, 11061111.
  • Thee S, Detjen AA, Wahn U & Magdorf K (2010) Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. Scandinavian Journal of Infectious Diseases42, 294298.
  • Thee S, Seddon JA, Donald PR et al. (2011) Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrobial Agents and Chemotherapy55, 55605567.
  • World Health Organization (2003) Treatment of tuberculosis: guidelines for national programmes. http://whqlibdoc.who.int/hq/2003/who_cds_tb_2003.313_eng.pdf
  • World Health Organization (2006) Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. http://www.who.int/childgrowth/standards/technical_report/en/
  • World Health Organization (2009) Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. http://www.who.int/entity/tb/challenges/interim_paediatric_fdc_dosing_instructions_sept09.pdf
  • World Health Organization (2012) Factsheet on childhood TB. No more crying, no more dying. Towards zero TB deaths in children. http://www.who.int/tb/challenges/children/en/
  • Zhu M, Starke JR, Burman WJ et al. (2002) Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy22, 686695.